Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma

NCT07079410 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Oral Squamous Cell Carcinoma (OSCC)
Oropharyngeal Squamous Cell Carcinoma
Resectable Oral and Oropharyngeal Squamous Cell Carcinoma

Interventions

DRUG: Sintilimab+Cetuximab

Sponsor

Shanghai Zhongshan Hospital